Sandoz

The company is headquartered in Basel, Switzerland, and has operated as an independent listed business since the Novartis spin-off in October 2023.

The group is led by chief executive Richard Saynor, who has run Sandoz since 2019. The business positions its model around scale manufacturing, a broad portfolio, and a growing biosimilars pipeline intended to offset long-term pricing pressure in commodity generics. 

In 2024, Sandoz emphasized a strategy centered on targeted biosimilars expansion and selective plays in “high-value” generics, while maintaining a global supply network and investing in product launches and lifecycle management. Company reporting highlights biosimilars as a key growth driver, alongside continued volume-led performance in generics. 

Recent operating updates have pointed to accelerating biosimilars momentum. In August 2025 (H1 2025 results), Sandoz reported double-digit biosimilars growth, noting that biosimilars represented 30% of net sales in the second quarter of 2025 for the first time. The company cited Europe and International performance and continued North America launches as contributors. 

Product news flow has focused on biosimilar rollouts and launch readiness. In late November 2025, the company announced a European launch of Afqlir (aflibercept biosimilar), adding to a wave of ophthalmology and immunology products moving through commercialization. 

Alongside execution, Sandoz has remained active on market-structure and access issues. In April 2025, it filed a U.S. antitrust lawsuit against Amgen related to Enbrel (etanercept), alleging barriers to biosimilar market entry. Separately, the company has commented publicly on policy proposals affecting European pricing and U.S. tariff risk as part of its broader access narrative.